The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: Proposal for a working hypothesis

Clinica Chimica Acta

Volumn 405, Issue 1-2, 2009, Pages 1-7

  Clerico, Aldo ^a,b   Fontana, Marianna ^a   Vittorini, Simona ^a   Emdin, Michele ^a  

^a CNR   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

BMI; BNP; Cardiac mortality; Natriuretic peptides; NT proBNP; Obesity; Sex steroids

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANDROGEN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ESTROGEN; NATRIURETIC FACTOR; SEX HORMONE; STEROID HORMONE;

ADIPOSE TISSUE; ASCITES; BODY MASS; CARDIOVASCULAR RISK; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; FEMALE GENITAL SYSTEM FUNCTION; GONAD FUNCTION; HEART DISEASE; HEART FUNCTION; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LIPOLYSIS; LIVER CIRRHOSIS; LUNG DISEASE; MALE GENITAL SYSTEM FUNCTION; METABOLIC SYNDROME X; MORTALITY; OBESITY; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REPRODUCTION; REVIEW; SEPSIS; SEX DIFFERENCE; SUBARACHNOID HEMORRHAGE;

ANIMALS; BODY WEIGHT; ENDOCRINE SYSTEM; GENDER IDENTITY; GONADAL STEROID HORMONES; HEART DISEASES; HUMANS; RISK FACTORS;

EID: 67349243313     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.03.050     Document Type: Review

References (75)

1. Clerico A., Recchia F.A., Passino C., and Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol, Heart Circ Physiol 290 (2006) H17-29
2. Balion C.M., Santaguida P., McKelvie R., et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem 41 (2008) 231-239
3. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 50 (2004) 33-50
4. Doust J.A., Glasziou P.P., Pietrzak E., and Dobson A.J. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164 (2004) 1978-1984
5. Clerico A., Fontana M., Zyw L., Passino C., and Emdin M. Comparison of the diagnostic accuracy of Brain Natriuretic Peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 53 (2007) 813-822
6. Balion C.M., McKelvie R.S., Reichert S., et al. Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool?. Clin Biochem 41 (2008) 266-276
7. Ewald B., Ewald D., Thakkinstian A., and Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 38 (2008) 101-113
8. Emdin M., Passino C., Prontera C., et al. Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. Clin Chem 53 (2007) 1264-1272
9. Tang W.H., Francis G.S., and Morrow D.A. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109
10. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 29 (2008) 2388-2442
11. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 288 (2002) 1252-1259
12. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., and Giannessi D. Circulating levels of cardiac natriuretic hormones in healthy adult subjects: effects of aging and sex. Clin Chem Lab Med 40 (2002) 371-377
13. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 (2002) 254-258
14. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
15. Kuroski de Bold M.L. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res 41 (1999) 524-531
16. Maffei S., Del Ry S., Prontera C., and Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci 101 (2001) 447-453
17. Ueda R., Yokouchi M., Suzuki T., Otomo E., and Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 114 (2003) 266-270
18. Baruch L., Glazer R.D., and Aknay N. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 148 (2004) 951-957
19. Das S.R., Drazner M.H., and Dries D.L. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112 (2005) 2163-2168
20. Chang A.Y., Abdullah S.M., and Jain T. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 49 (2007) 109-116
21. Dockery F., Bulpitt C.J., Agarwal S., et al. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrinol 68 (2008) 59-65
22. Sarzani R., Salvi F., Dessì-Fulgheri P., and Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 26 (2008) 831-843
23. Bayes-Genis A., DeFilippi C., and Januzzi Jr. J.L. Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol 101 3A (2008) 56-60
24. Kawano H., Nagayoshi Y., and Soejima H. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram. Menopause 15 (2008) 352-356
25. Hong M., Yan Q., and Tao B. Estradiol, progesterone and testosterone exposures affect the atrial natriuretic peptide gene expression in vivo in rats. Biol Chem Hoppe-Seyler 373 (1992) 213-218
26. Hwu C.M., Tsai S.C., Lau C.P., et al. Increased concentrations of atrial and plasma atrial natriuretic peptide in castrated male rats. Life Sci 52 (1993) 205-212
27. Matsubara H., Hirata Y., and Yoshimi H. Effects of steroid and thyroid hormones on synthesis of atrial natriuretic peptide by cultured atrial myocytes of rat. Biochem Biophys Res Commun 145 (1987) 336-343
28. Matsubara H., Hirata Y., and Yoshimi H. Ventricular myocytes from neonatal rats are more responsive to dexamethasone than atrial myocytes in synthesis of atrial natriuretic peptide. Biochem Biophys Res Commun 148 (1987) 1030-1038
29. Dockery F., Bulpitt C.J., and Agarwal S. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrinol 68 (2008) 59-65
30. LaPolt P.S., Leung K., Ishimaru R., Tafoya M.A., and You-hsin Chen J. Roles of cyclic GMP in modulating ovarian functions. Reprod Biomed Online 6 (2003) 15-23
31. Gutkowska J., Jankowski M., and Sairam M.R. Hormonal regulation of natriuretic peptide system during induced ovarian follicular development in the rat. Biol Reprod 61 (1999) 162-179
32. Jankowski M., Reis A.M., Mukaddam-Daher S., et al. C-type natriuretic peptide and the guanylyl cyclase receptors in the rat ovary are modulated by the estrous cycle. Biol Reprod 56 (1997) 59-66
33. Noubani A., Farookhi R., and Gutkowska J. B-type natriuretic peptide receptor expression and activity are hormonally regulated in rat ovarian cells. Endocrinology 141 (2000) 551-559
34. Ivanova M.D., Gregoraszczuk E.L., Augustowska K., Kolodziejczyk J., Mollova M.V., and Kehayov I.R. Localization of atrial natriuretic peptide in pig granulosa cells isolated from ovarian follicles of various size. Reprod Biol 3 (2003) 173-181
35. Walther T., and Stepan H. C-type natriuretic peptide in reproduction, pregnancy and fetal development. J Endocrinol 180 (2004) 17-22
36. Tsai E.M., Yang Y.Y., Lee T.T., Chang Y., Li S., and Lee J.N. Atrial natriuretic peptide inhibits ovarian functions in female mice. Eur J Obstet Gynecol Reprod Biol 119 (2005) 215-218
37. Johnson K.M., Hughes Jr. F.M., Fong Y.Y., Mathur R.S., Williamson H.O., and Gorospe W.C. Effects of atrial natriuretic peptide on rat ovarian granulosa cell steroidogenesis in vitro. Am J Reprod Immunol 31 (1994) 163-168
38. Zhang M., Tao Y., Xia G., et al. Atrial natriuretic peptide negatively regulates follicle-stimulating hormone-induced porcine oocyte maturation and cumulus expansion via cGMP-dependent protein kinase pathway. Theriogenology 64 (2005) 902-916
39. Zhang M., Tao Y., and Zhou B. Atrial natriuretic peptide inhibits the actions of FSH and forskolin in meiotic maturation of pig oocytes via different signalling pathways. J Mol Endocrinol 34 (2005) 459-472
40. Foresta C., Mioni R., and Caretto A. Specific binding and steroidogenetic effects of atrial natriuretic factor (ANF) in Leydig cells of rats. Arch Androl 19 (1987) 253-259
41. Foresta C., Mioni R., Miotto D., De Carlo E., Facchin F., and Varotto A. Stimulatory effects of alpha-hANP on testosterone secretion in man. J Clin Endocrinol Metab 72 (1991) 392-395
42. Khurana M.L., and Pandey K.N. Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: activation of cholesterol side-chain cleavage enzyme. Endocrinology 133 (1993) 2141-2149
43. Middendorff R., Müller D., Paust H.J., Davidoff M.S., and Mukhopadhyay A.K. Natriuretic peptides in the human testis: evidence for a potential role of C-type natriuretic peptide in Leydig cells. J Clin Endocrinol Metab 81 (1996) 4324-4328
44. Collin O., Lissbrant E., and Bergh A. Atrial natriuretic peptide, brain natriuretic peptide and c-type natriuretic peptide: effects on testicular microcirculation and immunohistochemical localization. Int J Androl 20 (1997) 55-60
45. El-Gehani F., Tena-Sempere M., Ruskoaho H., and Huhtaniemi I. Natriuretic peptides stimulate steroidogenesis in the fetal rat testis. Biol Reprod 65 (2001) 595-600
46. Lee T.T., Cheng B.H., Tsai E.M., et al. Chronic administration of atrial natriuretic peptide reduces testosterone production of testes in mice. J Androl 24 (2003) 912-917
47. Mehra M.R., Uber P.A., Park M.H., et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43 (2004) 1590-1595
48. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
49. Dessi-Fulgheri P., Sarzani R., and Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 11 (1998) 296-299
50. Daniels L.B., Clopton P., and Bhalla V. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the breathing not properly multinational study. Am Heart J 151 (2006) 999-1005
51. Krauser D., Lloyd-Jones D., and Chae C. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149 (2005) 744-750
52. McCord J., Mundy B.J., and Hudson M.P. Breathing Not Properly Multinational Study Investigators. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164 (2004) 2247-2252
53. Hunt S.A., American College of Cardiology, and American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
54. De Lemos J.A., and Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 101 (2008) 16A-20A [suppl]
55. Nir A., Lindinger A., and Rauh M. NT-pro-B-type natriuretic peptide in Infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30 (2009) 3-8
56. Lafontan M., Moro C., Berlan M., Crampes F., Sengenes C., and Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19 (2008) 130-137
57. Garruti G., Giusti V., and Nussberger J. Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes. Obesity 15 (2007) 2181-2189
58. Sarzani R., Marcucci P., and Salvi F. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes 32 (2008) 259-267
59. Dessi-Fulgheri P., Sarzani R., and Tamburrini P. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 15 (1997) 1695-1699
60. Licata G., Volpe M., Scaglione R., and Rubattu S. Salt-regulating hormones in young normotensive obese subjects: effects of saline load. Hypertension 23 1 Suppl (1994) I20-I24
61. Messerli F.H., Ventura H.O., Reisin E., et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 66 (1982) 55-60
62. Emdin M., Gastaldelli A., Muscelli E., et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 30 103 (2001) 513-519
63. Crandall D.L., Ferraro G.D., and Cervoni P. Effect of experimental obesity and subsequent weight reduction upon circulating atrial natriuretic peptide. Proc Soc Exp Biol Med 191 (1989) 352-356
64. Mattsson C., and Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem 14 (2007) 2918-2924
65. Blouin K., Boivin A., and Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 108 (2008) 272-280
66. Ordovas J.M. Gender, a significant factor in the cross talk between genes, environment, and health. Gen Med 4 (2007) S111-S122 [Suppl B]
67. Giannessi D., Andreassi M.G., Del Ry S., Clerico A., Colombo M.G., and Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 24 (2001) 8-16
68. Scotland R.S., Ahluwalia A., and Hobbs A.J. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 105 (2005) 85-93
69. Belo N.O., Sairam M.R., and Dos Reis A.M. Impairment of the natriuretic peptide system in follitropin receptor knockout mice and reversal by estradiol: implications for obesity-associated hypertension in menopause. Endocrinology 149 (2008) 1399-1406
70. García-Romero G., and Escobar-Morreale H.F. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev 2 (2006) 39-49
71. Shirley S., Davis L.L., and Carlson B.W. The relationship between body mass index/body composition and survival in patients with heart failure. J Am Acad Nurse Pract 20 (2007) 326-332
72. Oreopoulos A., Padwal R., Kalantar-Zadeh K., Fonarow G.C., Norris C.M., and McAlister F.A. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156 (2008) 13-22
73. Kalantar-Zadeh K., Kilpatrick R.D., Kuwae N., and Wu D.Y. Reverse epidemiology: a spurious hypothesis or a hardcore reality?. Blood Purif 23 (2005) 57-63
74. Kalantar-Zadeh K., Anker S.D., Horwich T.B., and Fonarow G.C. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 101 Suppl 11A (2008) 89E-103E
75. Tostain J.L., and Blanc F. Testosterone deficiency: a common, unrecognized syndrome. Nat Clin Pract Urol 5 (2008) 388-396